Instil Bio, Inc. (TIL) Research

Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.

Market snapshot

Symbol
TIL
Price
$7.50
Day change
-0.79%
Market cap
$50.9M
P/E ratio
-1.07x
52-week range
5.67-33.833
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$7.00

Peer companies

  • Atossa Therapeutics, Inc. (ATOS)
  • InflaRx N.V. (IFRX)
  • MacroGenics, Inc. (MGNX)
  • Oncolytics Biotech Inc. (ONCY)
  • Pliant Therapeutics, Inc. (PLRX)
  • Surrozen, Inc. (SRZN)
  • Shattuck Labs, Inc. (STTK)
  • Tevogen Bio Holdings Inc. (TVGN)

Recent insider activity

  • McGaughy R Kent Jr — A-Award (6500 shares) on 2026-06-11
  • Matcham George — A-Award (6500 shares) on 2026-06-11
  • Gibson Neil W — A-Award (0 shares) on 2026-06-11
  • Binder Gwendolyn — A-Award (6500 shares) on 2026-06-11
  • Laumas Sandeep — M-Exempt (13000 shares) on 2025-09-10

Open Instil Bio, Inc. (TIL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.